Study Details

Back to Search Results

A Study evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients with Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT00889382

Astellas Study ID

The unique identification code given by the study sponsor.

OSI-906-202

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2009-010319-34

Follow Trial

Condition

Ovarian Cancer, Advanced/Metastatic Cancer

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Aug 2009 - Aug 2014

Masking

None (Open Label)

Enrollment number

152

A Phase 1/2 Study evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients with Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients with Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Mater Adult Hospital

South Brisbane, Australia, 4101

University College Hospital

London, United Kingdom, WC1E 6BT

Sir Charles Gairdner Hospital

Perth, Australia, 6009

St. John of Gog Hospital, Subiaco

Subiaco, Australia, 6008

Mount Vernon Cancer Center

Northwood, United Kingdom, HA62RN

Border Medical Oncology

Wodonga, Australia, 3690

Clinical Caunty Hospital Mures

Mures, Romania, 540072

Department of Obstetrics and Gynecology, University of California, Irvine

Orange, United States, 92868

Princess Margaret Hospital

Toronto, Canada, M5G 2M9

Sity Clinical Oncology

St. Petersburg, Russian Federation, 198255

WestMead Hospital

WestMead, Australia, 2145

Instituto Europeo di Oncologia

Milan, Italy, 20141

Oddzial Radioterapii

Poznan, Poland, 61 866

University of Oklahoma Health Sciences Center

Oklahoma City, United States, 73104

Duke University Medical Center

Durham, United States, 27710

Ospedale San Giovanni

Bellinzona, Switzerland, CH-6500

Christie NHS Foundation Trust

Withington, United Kingdom, M20 4BX

State Institution Medical Radiology Scientific Center

Obninsk, Russian Federation, 249036

St. John of God Hospital, Bunbury

Bunbury, Australia, 6230

Ochsner Clinic Foundation

New Orleans, United States, 70121

Royal Marsden Hospital

London, United Kingdom, SW3 6JJ

Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia Radiologie

Cluj Napoca, Romania, 400015

General University Hospital, Department of Obstetrics and Gynecology

Prague, Czech Republic, 212000

Klinika Onkologii AM w Poznaniu

Poznan, Poland, 61-878

Mayo Clinic

Scottsdale, United States, 85259

McGill University

Montreal, Canada, H3T 1E2

Central Clinical Hospital

Moscow, Russian Federation, 129128

Morristown Memorial Hospital

Morristown, United States, 07960

Royal Adelaide Hospital

North Terrace, Australia, 5000

Horizon Oncology Center

Lafayette, United States, 47906

Oncology IDI- IRCSS

Roma, Italy, 67100

Moscow City Oncology Hospital

Moscow, Russian Federation, 143423

University Hospital Hradec Kralove

Kralove, Czech Republic, 50005

Blumenthal Cancer Center - Main

Charlotte, United States, 28204

III Oddzial Onkologii Ginekologicznej

Lublin, Poland, 20-090

Drug Development Unit Royal Mardsen NHS Foundation Trust

Sutton, United Kingdom, SM2 5PT

Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia de Oncologie Medicala

Cluj Napoca, Romania, 400015

Launceston General Hospital

Launceston, Australia, 7250

Ospedale di Carpi, AUSL di Modena

Carpi, Italy, 91012

Churchill Hospital

Oxford, United Kingdom, OX37LI

Oncology Medical Centre SCM

Iasi, Romania, 700106

Frankston Hospital

Frankston, Australia, 3199

Juravinski Cancer Center

Hamilton, Canada, L8V 5C2

Universitaria di Bologna Policlinico

Bologna, Italy, 40138

The Christie NHS Foundation Trust

Manchester, United Kingdom, M20 4BX

University Hospital Ostrava

Ostrava- Poruba, Czech Republic, 70852

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo